• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Ghrelin-receptor agonists may be beneficial in cancer anorexia-cachexia syndrome

byKhang DinhandDavid Wang
December 21, 2014
in Chronic Disease, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Patients with cancer anorexia-cachexia syndrome who received anamorelin gained significantly more lean muscle mass compared to the placebo group.

2. Severe adverse events related to the anamorelin treatment group were relatively rare and included fatigue, asthenia, atrial fibrillation, and dyspnea.

Evidence Rating Level: 2 (Good)

Study Rundown: Patients with advanced cancer commonly suffer from cachexia, defined as a progressive loss of skeletal muscle mass.  Cachexia is a poor prognostic indicator and is associated with reduced treatment tolerance and response and decreased overall survival.  Furthermore, the syndrome of cachexia-anorexia responds poorly to current appetite stimulant strategies. The ghrelin receptor (GRLNR) pathway is a novel therapeutic approach due to its putative anabolic activity that is both appetite-dependent and independent. The purpose of this trial is to analyze the utility and safety of anamorelin, an orally available, selective GRLNR agonist, for the treatment of cancer anorexia-cachexia. In a pooled analysis of two phase II trials, 82 patients with advanced cancer were randomized, in a double-blind fashion, to either 12 weeks of anamorelin or placebo. The primary endpoint was change in lean body mass over the treatment period.  The authors demonstrated that patients in the anamorelin group had a significant increase in lean body mass compared to the placebo group. Patients receiving anamorelin also reported higher quality of life compared to those receiving placebo. Side effects associated with the treatment arm were rare, but included fatigue, asthenia, atrial fibrillation, and dyspnea. The results of this study support the use of anamorelin as a potential intervention in cancer anorexia-cachexia syndrome. However, the study is limited by its small sample size and its lack of stratification of important cofounding variables, such as use of concurrent cancer therapies. Additional larger randomized control trials are needed to assess the effectiveness of GRLNRs.

Click to read the study in Lancet Oncology

Relevant Reading: Cancer Cachexia and Fat-Muscle Physiology

In-Depth [randomized controlled trial]: This study is a pooled analysis of two phase II trials analyzing the effectiveness of anamorelin in cancer anorexia-cachexia syndrome. Eligible patients were 18 years or older diagnosed with advanced or incurable cancer with involuntary loss of 5% of body mass over the past 6 months. A combined 44 and 38 patients were randomized to receive 12 weeks of anamorelin or placebo, respectively. Patient age within the cohort ranged from 19 to 94 years with an average of 65.2 years. The most common primary malignancies were lung cancer, followed by colon, genitourinary, and breast. The primary endpoint was change in lean body mass as measured by dual-energy x-ray absorptiometry (DXA). At the end of the treatment period, patients randomized to anamorelin gained an average of 1.89 kg (95% CI: 0.84 to 2.95 kg) compared to those receiving placebo, who lost an average of 0.2 kg (95% CI: -1.23 to 0.83 kg). The difference of 2.09 kg was statistically significant (p=0.0006). The most common treatment-related adverse events in the anamorelin group were diarrhea (1%) and fatigue (1%) while asthenia (5%), atrial fibrillation (5%), and dyspnea (5%) were the most common treatment-unrelated adverse events. Interestingly, for both treatment and placebo arms, more than 60% of patients were male, which may have magnified the anabolic effect of anamorelin.

RELATED REPORTS

Wellness Check: Sleep

Increases in muscle-strengthening activities may reduce mortality risk and certain diseases

COVID-19 pandemic associated with reductions in delivery of cancer care services in Ontario, Canada

More from this author: Erlotinib does not demonstrate increased survival in ovarian epithelial carcinomas, Afatinib shows increased progression-free survival in non-small-cell lung cancer, New method may predict response to chemotherapy for lung cancer, Escalated-dose radiotherapy did not increase survival in prostate cancer, Stereotactic radiosurgery promising for patients with multiple brain metastases

Image: PD

©2014 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. No article should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2 Minute Medicine, Inc.

Tags: anamorelincancerghrelin
Previous Post

Long-term active surveillance may be safe in low-risk prostate cancer

Next Post

Less wound complications with suture skin closure after C-section

RelatedReports

Sleep duration, sleepiness, chronotype have variable associations with teen self-regulation
Wellness

Wellness Check: Sleep

May 26, 2022
Exercise improves aromatase inhibitor-induced arthralgia in breast cancer survivors
Cardiology

Increases in muscle-strengthening activities may reduce mortality risk and certain diseases

May 3, 2022
Chronic Disease

COVID-19 pandemic associated with reductions in delivery of cancer care services in Ontario, Canada

April 29, 2022
Variability in interpretation of breast biopsy slides associated with low verification of atypia and ductal carcinoma in situ
Oncology

Comparison of mastectomy and breast reconstruction versus conservative surgery with radiation

April 26, 2022
Next Post
Less wound complications with suture skin closure after C-section

Less wound complications with suture skin closure after C-section

Autism associated with air pollution exposure during pregnancy

Autism associated with air pollution exposure during pregnancy

Updated sports physical form not required in most states

Updated sports physical form not required in most states

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
  • #VisualAbstract: Ruxolitinib shows long-term safety and efficacy in inadequately controlled polycythaemia vera without splenomegaly
  • Wellness Check: Sleep
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.